The trajectory from rituximab to glycoengineered CD20 antibodies, radioimmunoconjugates to highly potent CD20 × CD3 bispecifics, and CD38/SLAMF7/BCMA antibodies to structurally optimized bispecific platforms in multiple myeloma illustrates the remarkable breadth of innovation achieved over the past two decades. Here, CD38 is linked to plasma cell myeloma.